Trials / Completed
CompletedNCT04868292
Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 in Healthy Volunteers
A Phase 1, Single-Center, Open-Label Study to Assess the Intrapulmonary Pharmacokinetics of SPR206 by Comparing the Plasma, Epithelial Lining Fluid, and Alveolar Macrophage Concentrations Following the Intravenous Administration of SPR206 in Healthy Volunteers
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 34 (actual)
- Sponsor
- Spero Therapeutics · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
To evaluate the intrapulmonary pharmacokinetics (PK), including epithelial lining fluid (ELF) and alveolar macrophage (AM) concentrations, of SPR206 as well as plasma concentrations of SPR206 in healthy adult volunteers.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SPR206 | Three 100 mg SPR206 intravenous doses administered every 8 hours |
Timeline
- Start date
- 2021-06-03
- Primary completion
- 2021-09-16
- Completion
- 2021-09-29
- First posted
- 2021-04-30
- Last updated
- 2021-11-17
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT04868292. Inclusion in this directory is not an endorsement.